Endoscopes Services Market: as STERIS Healthcare segment USD 3.61 Billion FY2024 in the third consecutive year of double-digit constant currency organic growth anchors global endoscope reprocessing and repair services demand, Olympus On-Demand sterile scope delivery launched in Australia September 2024 establishes the sterilization-as-a-service commercial model converting hospital CAPEX into per-procedure OPEX, so AI-cloud endoscopy subscription revenue is emerging through Olympus OLYSENSE CADDIE polyp detection platform and Odin Vision acquisition, and disposable scope growth together with skilled technician workforce shortages constrain reprocessing service market expansion.

The global endoscopes services market size was USD 4.82 Billion in 2025 and is expected to register a revenue CAGR of 6.6% during the forecast period. Market revenue growth is driven by factors such as expanding endoscopic procedure volumes generating proportional validated reprocessing cycle demand at each facility, sterilization-as-a-service and AI-cloud endoscopy subscription models converting per-procedure reprocessing cost from hospital operational expense into managed service contracts, and as well as STERIS Healthcare segment third consecutive year of double-digit constant currency organic growth confirming the commercial scale of the endoscope reprocessing services category. The first driving factor is the sustained expansion of endoscopic diagnostic and therapeutic procedure volumes generating proportional demand for validated reprocessing services, with more than 20 million gastrointestinal examinations performed annually in the United States alone per 2024 Scientific Reports meta-analysis, each requiring a complete documented reprocessing cycle, and FDA 2024 supplemental duodenoscope guidance reinforcing validated HLD and sterilization requirements at US hospitals and ASCs and STERIS Healthcare segment delivering 13% constant currency organic growth FY2024 as the third consecutive year of double-digit growth confirmed by CEO Dan Carestio as driven primarily by United States procedural volume growth generating sustained AER service and HLD consumable revenue. The second driving factor is the commercial development of sterilization-as-a-service and AI-cloud endoscopy subscription models that convert hospital reprocessing from capital equipment ownership and operational management into per-procedure service contracts, demonstrated by Olympus opening Sapphire sterile scope facility in Melbourne September 2024 under the On-Demand model delivering sterile ready-to-use flexible endoscopes per-procedure, and by Olympus acquiring Odin Vision and unveiling OLYSENSE Platform with CADDIE AI polyp detection at DDW May 2025 generating subscription-based service revenue from cloud-connected colonoscopy quality improvement. The third driving factor is the scope repair and maintenance services category generating recurring revenue from the flexible endoscope installed base at hospital and ASC endoscopy suites, with FUJIFILM India expanding its Mumbai service centre for bronchoscope and gastroscope repair in July 2024 and Olympus Innovation Ventures Fund II committing USD 150 Million in December 2025 to digital health and endoscopy MedTech innovation. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way AER capital equipment installation creates a structural consumable pull-through lock-in that sustains recurring validated chemistry and service contract revenue per installed instrument base well above what standalone consumable sales to non-AER accounts would generate, which allows AER manufacturers and service operators to generate predictable long-term revenue from each AER capital placement. Once a hospital installs an AER and validates a specific reprocessing protocol combining a specific AER model with a specific HLD chemistry formulation, substituting either the AER or the HLD chemistry requires revalidation of the complete reprocessing protocol through independent testing, creating a structural deterrent to chemistry or equipment switching that sustains recurring chemistry and service revenue for the initial validated combination. As a result, demand and revenue share are concentrating around the service providers with the largest AER installed bases and the deepest validated chemistry consumable portfolios, and the forecast tilts toward these installed-base service platforms rather than contract service organisations competing on labour cost alone. For instance, in October 2024, Olympus received CE Mark approval under MDR for CADDIE, CADU, and SMARTIBD cloud-based AI medical devices forming the Intelligent Endoscopy Ecosystem, one of several commercial and regulatory events that reshaped the competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the expanding volume of endoscopic diagnostic and therapeutic procedures generating proportional non-discretionary reprocessing service demand, because each additional procedure requires a complete validated disinfection cycle with documented chemical concentration, cycle parameters, and scope serial number regardless of whether the procedure is elective or emergent, creating a predictable recurring revenue stream that grows in direct proportion to procedure volume growth. Validated reprocessing services work commercially because the FDA 2024 supplemental duodenoscope guidance and Joint Commission 2024 HLD cycle tracking standards together require documented, traceable reprocessing at every US hospital and ASC performing endoscopy, converting reprocessing from an operational expense to a compliance requirement that cannot be deferred or eliminated without regulatory exposure. More than 20 million gastrointestinal examinations are performed annually in the United States alone per 2024 Scientific Reports meta-analysis, each requiring a complete documented reprocessing cycle. STERIS Healthcare 13% constant currency organic growth FY2024 confirmed by CEO Dan Carestio as driven primarily by United States strength represents the third consecutive year of double-digit constant currency growth anchored in AER service contract and HLD consumable pull-through revenue from the Cantel Medivators AER installed base. Olympus Endoscopic Solutions Division reported FY2025 revenues of approximately JPY 636.1 Billion at 8% growth driven by North America EVIS X1 system sales and On-Demand service expansion. These are some of the key factors driving revenue growth of the market.

The second driver is the commercial development of sterilization-as-a-service and AI-cloud endoscopy subscription models that convert hospital reprocessing from a capital equipment and staffing investment into a per-procedure service fee, shifting the financial model from CAPEX to OPEX and from in-house compliance management to contracted service provider accountability. Sterilization-as-a-service works commercially because hospital chief financial officers managing capital allocation decisions can replace a USD 150,000 AER capital investment plus sterile processing staffing cost with a predictable per-procedure service fee that scales linearly with procedure volume growth, eliminating equipment obsolescence risk, compliance management burden, and peak-demand staffing cost in a single contract. Olympus opened Sapphire sterile scope facility in Melbourne in September 2024 under the On-Demand model delivering sterile ready-to-use flexible endoscopes to participating hospitals on a per-procedure basis, the first Asia Pacific dedicated sterile scope delivery hub after the model launched in Europe, Asia, and Japan from March 2021 and extended to the US and China in fiscal year 2024. Olympus acquired Odin Vision and unveiled OLYSENSE Platform with CADDIE AI polyp detection at DDW May 2025, enabling subscription-based service revenue from cloud-connected colonoscopy quality improvement. Olympus received CE Mark approval in October 2024 for CADDIE, CADU, and SMARTIBD cloud AI devices forming the Intelligent Endoscopy Ecosystem, and launched Innovation Ventures Fund II with USD 150 Million in December 2025 to accelerate investment in endoscopy, diagnostics, and digital health. These are some of the key factors driving revenue growth of the market.

STERIS paid USD 4.60 Billion enterprise value for Cantel in 2021 despite Cantel generating approximately USD 1.00 Billion in annual revenue at the time. The recurring consumable revenue model against the AER installed base was the acquisition thesis. STERIS is executing against that thesis with 13% constant currency organic growth for three consecutive years. The consumable lock-in is structural: once a hospital validates a specific AER and HLD chemistry combination, chemistry substitution requires revalidation, creating multi-year switching barriers that sustain per-procedure chemistry revenue for the validated combination supplier.

The third driver is the geographic expansion of scope repair, maintenance, and service centre infrastructure into Asia Pacific and Latin America markets where growing flexible endoscope installed bases are generating repair and maintenance service demand that exceeds the capacity of existing global service centre networks. Scope repair services work commercially because flexible endoscopes cost USD 15,000 to USD 40,000 per unit for capital replacement, creating a strong economic case for manufacturer or third-party repair services that restore full functionality at USD 3,000 to USD 8,000 per repair episode and extend the useful life of the endoscope inventory beyond the standard 5 to 7 year replacement cycle. FUJIFILM India expanded its Mumbai service centre in July 2024 for bronchoscope and gastroscope repair with reduced turnaround times, reflecting the growing repair service demand at Indian private and academic hospital endoscopy departments accumulating flexible endoscope inventory as gastroenterology and pulmonology procedure volumes expand. Olympus FY2025 Endoscopic Solutions Division revenue of JPY 636.1 Billion at 8% growth was led by North America double-digit growth from EVIS X1 system sales, with service revenue components growing in parallel with hardware placements generating future repair and maintenance demand. The Olympus On-Demand model also creates a captive repair and maintenance revenue stream within the sterile scope delivery service contract, as Olympus maintains the sterile endoscope inventory quality at the Sapphire facility and manages scope repair without hospital administrative burden. These are some of the key factors driving revenue growth of the market.

However, the endoscopes services market faces adoption constraints from single-use disposable endoscope growth eliminating reprocessing service revenue at converting departments. Because single-use endoscopes are growing at approximately 12.5% annually, with Ambu aScope Cysto HD FDA cleared June 2025 for percutaneous nephrolithotomy representing expanding single-use penetration into urology applications previously requiring reusable reprocessed scopes, and with Boston Scientific and Olympus single-use accessories growing adoption in high-risk infection control ERCP settings, each converted procedure scope department eliminates its per-procedure reprocessing service and HLD consumable demand, creating a structural headwind for service revenue growth in bronchoscopy and ERCP applications that is partially offset by growing GI endoscopy colonoscopy and gastroscopy service volumes. Skilled sterile processing technician workforce shortages constrain outsourced reprocessing service model adoption at community hospitals and ASCs in Asia Pacific and Latin America, where the transition from in-house to contracted reprocessing requires documented compliance handover that is complicated by inadequate baseline reprocessing documentation at facilities with limited sterile processing staffing infrastructure. Iran-US sanctions disruption to HLD chemical supply chains maintains elevated disinfectant input costs for European and Asian service operators through 2026, compressing service contract gross margins at a time when multi-year hospital service contract price renegotiation is constrained by original pricing terms. These factors substantially limit endoscopes services market growth over the forecast period.

Based on service type, the global endoscopes services market is segmented into automated endoscope reprocessing services, scope repair maintenance and loaner programme services, manual HLD and cleaning chemistry services, sterilization-as-a-service and on-demand scope delivery, and AI cloud endoscopy and digital compliance subscriptions. Automated endoscope reprocessing services hold the largest revenue share at approximately 42%. Sterilization-as-a-service is expected to register the most rapid revenue growth rate in the global endoscopes services market over the forecast period, driven by Olympus On-Demand global rollout across Europe, Japan, Asia, US, and China, with the Sapphire Melbourne facility as the Asia Pacific template for per-procedure sterile scope delivery that converts hospital AER capital and compliance management into a managed service relationship.

Based on end-use, the global endoscopes services market is segmented into hospitals and academic medical centres, ambulatory surgical centres, and specialty endoscopy clinics. Hospitals hold the largest revenue share, processing the highest endoscopy service volume across the broadest scope inventory at hospital gastroenterology, pulmonology, and urology endoscopy suites. Ambulatory surgical centres are expected to register the fastest revenue growth rate in the global endoscopes services market over the forecast period, driven by the migration of colonoscopy, upper GI endoscopy, and outpatient bronchoscopy to ambulatory settings, with over 53% of US endoscopy device revenue generated at ASC settings per industry estimates, creating a growing ASC endoscope reprocessing service and AER installation demand that both STERIS Medivators and Olympus On-Demand are targeting through tailored ASC service contract programmes.

Based on regional analysis, the endoscopes services market in North America accounted for largest revenue share in 2025. STERIS Healthcare outperformance driven primarily by United States strength confirmed by CEO Dan Carestio in Q4 FY2024 earnings call, FDA regulatory enforcement requiring validated scope reprocessing documentation, and the Cantel Medivators AER installed base generating consumable pull-through revenue anchor the North American position. STERIS acquired US Endoscopy in 2012 for USD 270 Million and Cantel Medical for USD 4.60 Billion enterprise value in June 2021, establishing the combined AER service and HLD chemistry consumable infrastructure that generates the majority of US endoscopes services market revenue.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. EU surveillance data attribute more than 3.5 million healthcare-associated infections to reusable devices annually, creating regulatory pressure toward validated automated reprocessing and digital compliance tracking. NHS contracts exceeding GBP 250,000 awarded in 2024 reflect hospital moves toward validated decontamination equipment procurement. The ongoing Iran-US sanctions and Strait of Hormuz disruption affect HLD chemical supply chains, maintaining elevated disinfectant input costs for European reprocessing service operators through 2026 and compressing service gross margins on chemistry-intensive AER service contracts.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan has the highest per-capita flexible endoscopy procedure rate globally, anchoring the largest Asia Pacific endoscopes services market. Olympus On-Demand was extended to China during FY2024. FUJIFILM India expanded the Mumbai service centre in July 2024. Olympus Australia opened Sapphire Melbourne in September 2024 as the first Asia Pacific sterile scope delivery facility. India endoscopic procedures are growing faster than Japan per Olympus press office statements, with infection control infrastructure still evolving, creating opportunity for outsourced reprocessing service models that bypass inadequate in-house sterile processing capacity.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscopy services markets. Brazil's growing GI endoscopy procedure volumes at private hospital gastroenterology departments are generating scope repair and maintenance service demand, and the indirect effects of Iran-US sanctions on South American chemical supply chains have maintained elevated HLD consumable costs in Brazilian endoscopy service provider supply chains through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and UAE represent the primary commercial markets. GCC healthcare system modernisation under Saudi Vision 2030 includes investment in sterile processing department infrastructure incorporating automated endoscope reprocessing systems at tertiary hospitals, with King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi operating advanced endoscope reprocessing programmes that generate scope repair, maintenance, and reprocessing service revenue.